Anti-Chol-1 Antigen, GQ1bα, Antibodies Are Associated with Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ariga, Toshio ^a   Kubota, Masaru ^b   Nakane, Makoto ^c   Oguro, Kenji ^b   Yu, Robert K ^a   Ando, Susumu ^d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Oyama Orthopedics and Internal Medicine Hospital   (Japan)

^c TEIKYO UNIVERSITY MIZONOKUCHI HOSPITAL   (Japan)

^d Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLINERGIC SPECIFIC ANTIGEN 1 ALPHA ANTIBODY; GANGLIO N TETRAOSYL GANGLIOSIDE ANTIBODY; GANGLIOSIDE GM1; GANGLIOSIDE GQ 1B ALPHA ANTIBODY; GANGLIOSIDE GQ 1B ANTIBODY; GANGLIOSIDE GT1B ANTIBODY; GLYCOSPHINGOLIPID ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MALE; MULTIINFARCT DEMENTIA;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; ANTIGENS, SURFACE; AUTOANTIBODIES; CASE-CONTROL STUDIES; CATTLE; DEMENTIA, VASCULAR; GANGLIOSIDES; HUMANS;

EID: 84878165160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063326     Document Type: Article

References (49)

1. Nussbaum RL, Ellis CE, (2003) Alzheimer's disease and Parkinson's disease. N Engl J Med 348: 1356-1364.
2. Ariga T, McDonald MP, Yu RK, (2008) Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. J Lipid Res 49: 1157-1175.
3. Ariga T, Miyatake T, Yu RK, (2010) Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies-a review. J Neurosci Res 88: 2303-2315.
4. Yu RK, (1994) Development regulation of ganglioside metabolism. Prog Brain Res 101: 31-44.
5. Yu RK, Usuki S, Ariga T, (2006) Ganglioside molecular mimicry and its pathological roles in Guillain-Barre syndrome and related diseases. Infect Immun 74: 6517-6527.
6. Yuki N, Ariga T, (1997) Antibodies to fucogangliosides in neurological diseases. J Neurol Sci 150: 81-84.
7. Lehmann HC, Lopez PH, Zhang G, Ngyuen T, Zhang J, et al. (2007) Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 27: 27-34.
8. Chapman J, Sela BA, Wertman E, Michaelson DM, (1988) Antibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci Lett 86: 235-240.
9. Ando S, Hirabayashi Y, Kon K, Inagaki F, Tate S, et al. (1992) A trisialoganglioside containing a sialyl alpha 2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1 alpha. J Biochem 111: 287-290.
10. Hirabayashi Y, Nakao T, Irie F, Whittaker VP, Kon K, et al. (1992) Structural characterization of a novel cholinergic neuron-specific ganglioside in bovine brain. J Biol Chem 267: 12973-12978.
11. Ando S, Yu RK, (1977) Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. J Biol Chem 252: 6247-6250.
12. Ariga T, Yu RK, (1987) Isolation and characterization of ganglioside GM1b from normal human brain. J Lipid Res 28: 285-291.
13. Ariga T, Sekine M, Yu RK, Miyatake T, (1984) Isolation and characterization of a novel disialoganglioside from bovine adrenal medulla. Arch Biochem Biophys 232: 305-309.
14. Ren S, Scarsdale JN, Ariga T, Zhang Y, Klein RA, et al. (1992) O-acetylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. J Biol Chem 267: 12632-12638.
15. Kohriyama T, Kusunoki S, Ariga T, Yoshino JE, DeVries GH, et al. (1987) Subcellular localization of sulfated glucuronic acid-containing glycolipids reacting with anti-myelin-associated glycoprotein antibody. J Neurochem 48: 1516-1522.
16. Freddo L, Ariga T, Saito M, Macala LC, Yu RK, et al. (1985) The neuropathy of plasma cell dyscrasia: binding of IgM M-proteins to peripheral nerve glycolipids. Neurology 35: 1420-1424.
17. Okada N, Yasuda T, Tsumita T, Okada H, (1983) Activation of the alternative complement pathway by natural antibody to glycolipids in guinea-pig serum. Immunology 50: 75-84.
18. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, et al. (2000) Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord 11: 36-38.
19. Schott K, Wormstall H, Dietrich M, Klein R, Batra A, (1996) Autoantibody reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Psychiatry Res 59: 251-254.
20. Hatzifilippou E, Koutsouraki E, Banaki T, Traka M, Costa VG, et al. (2008) Antibodies against GM1 in demented patients. Am J Alzheimers Dis Other Demen 23: 274-279.
21. Mitzutamari RK, Kremer LJ, Basile EA, Nores GA, (1998) Anti-GM1 ganglioside IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy. J Neurosci Res 51: 237-242.
22. Kasai N, Pachner AR, Yu RK, (1986) Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 75: 33-42.
23. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, et al. (2009) Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 46: 3037-3049.
24. Mizutamari RK, Wiegandt H, Nores GA, (1994) Characterization of anti-ganglioside antibodies present in normal human plasma. J Neuroimmunol 50: 215-220.
25. Plumb J, McQuaid S, Mirakhur M, Kirk J, (2002) Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 12: 154-169.
26. Chen X, Gawryluk JW, Wagener JF, Ghribi O, Geiger JD, (2008) Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation 5: 12.
27. Desai BS, Monahan AJ, Carvey PM, Hendey B, (2007) Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant 16: 285-299.
28. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, et al. (2010) Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225: 519-528.
29. Vyshkina T, Kalman B, (2008) Autoantibodies and neurodegeneration in multiple sclerosis. Lab Invest 88: 796-807.
30. Bjartmar C, Trapp BD, (2003) Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 5: 157-164.
31. Acarin N, Rio J, Fernandez AL, Tintore M, Duran I, et al. (1996) Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 93: 99-103.
32. Zaprianova E, Majtenyi K, Deleva D, Mikova O, Filchev A, et al. (2004) Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis. Ideggyogy Sz 57: 94-99.
33. Mata S, Lolli F, Soderstrom M, Pinto F, Link H, (1999) Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 5: 379-388.
34. Sadatipour BT, Greer JM, Pender MP, (1998) Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44: 980-983.
35. Pender MP, Csurhes PA, Wolfe NP, Hooper KD, Good MF, et al. (2003) Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 10: 63-66.
36. Marconi S, Acler M, Lovato L, De Toni L, Tedeschi E, et al. (2006) Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Mult Scler 12: 302-308.
37. Haghighi S, Lekman A, Nilsson S, Blomqvist M, Andersen O, (2012) Myelin glycosphingolipid immunoreactivity and CSF levels in multiple sclerosis. Acta Neurol Scand 125: 64-70.
38. Ilyas AA, Chen ZW, Cook SD, (2003) Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 139: 76-80.
39. Zappia M, Crescibene L, Bosco D, Arabia G, Nicoletti G, et al. (2002) Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 106: 54-57.
40. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, et al. (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142: 223-236.
41. Ravindranath MH, Muthugounder S, Saravanan TS, Presser N, Morton DL, (2005) Human antiganglioside autoantibodies: validation of ELISA. Ann N Y Acad Sci 1050: 229-242.
42. Kanda T, Iwasaki T, Yamawaki M, Tai T, Mizusawa H, (2000) Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model. Neurology 55: 585-587.
43. Winer JB, (2001) Guillain Barre syndrome. Mol Pathol 54: 381-385.
44. Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, et al. (2000) Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 68: 191-195.
45. Derrington EA, Borroni E, (1990) The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. Brain Res Dev Brain Res 52: 131-140.
46. Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK, (2007) Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J Neurochem 103: 2327-2341.
47. Ariga T, Yanagisawa M, Wakade C, Ando S, Buccafusco JJ, et al. (2010) Ganglioside metabolism in a transgenic mouse model of Alzheimer's disease: expression of Chol-1alpha antigens in the brain. ASN Neuro 2: e00044.
48. Chapman J, Bachar O, Korczyn AD, Wertman E, Michaelson DM, (1988) Antibodies to cholinergic neurons in Alzheimer's disease. J Neurochem 51: 479-485.
49. Foley P, Bradford HF, Docherty M, Fillit H, Luine VN, et al. (1988) Evidence for the presence of antibodies to cholinergic neurons in the serum of patients with Alzheimer's disease. J Neurol 235: 466-471.